Table 1.
Demographic and disease characteristics of the RA patients at baseline (full analysis set)a
| RAPID‐3 (n = 368) | CDAI (n = 365) | All (n = 733) | |
|---|---|---|---|
| Age, mean years | 54.0 | 55.7 | 54.9 |
| Female, no. (%) | 279 (75.8) | 292 (80.0) | 571 (77.9) |
| RA disease duration | |||
| Mean ± SD years | 8.8 ± 9.3 | 9.1 ± 8.9 | 8.9 ± 9.1 |
| <2 years, no. (%) of patients | 99 (26.9) | 71 (19.5) | 170 (23.2) |
| ≥2 years, no. (%) of patients | 269 (73.1) | 294 (80.5) | 563 (76.8) |
| DAS28‐ESR score, mean ± SD | 6.3 ± 1.1 | 6.3 ± 1.1 | 6.3 ± 1.1 |
| RAPID‐3 score, mean ± SD | 16.2 ± 5.4 | 16.0 ± 5.8 | 16.1 ± 5.6 |
| CDAI score, mean ± SD | 40.2 ± 13.2 | 40.2 ± 13.1 | 40.2 ± 13.2 |
| SDAI score, mean ± SD | 41.5 ± 13.7 | 41.4 ± 13.7 | 41.4 ± 13.7 |
| Swollen joint count, mean ± SD | 12.2 ± 5.7 | 12.2 ± 5.6 | 12.2 ± 5.7 |
| Tender joint count, mean ± SD | 15.7 ± 6.8 | 15.9 ± 6.8 | 15.8 ± 6.8 |
| CRP, mean ± SD mg/liter | 12.9 ± 18.6 | 11.6 ± 18.3 | 12.2 ± 18.5 |
| ESR, mean ± SD mm/hour | 39.2 ± 27.2 | 37.5 ± 28.1 | 38.4 ± 27.6 |
| MDHAQ function score, mean ± SD | 3.6 ± 1.9 | 3.6 ± 1.9 | 3.6 ± 1.9 |
| <2 years’ disease duration | 3.3 ± 1.9 | 3.6 ± 1.9 | 3.4 ± 1.9 |
| ≥2 years’ disease duration | 3.7 ± 1.9 | 3.6 ± 1.9 | 3.6 ± 1.9 |
| MDHAQ pain score, mean ± SD | 6.6 ± 2.0 | 6.5 ± 2.2 | 6.5 ± 2.1 |
| <2 years’ disease duration | 6.4 ± 2.0 | 6.5 ± 2.5 | 6.4 ± 2.2 |
| ≥2 years’ disease duration | 6.6 ± 2.1 | 6.5 ± 2.2 | 6.6 ± 2.1 |
| Patient's global health status estimate, mean ± SD | 6.1 ± 2.2 | 5.8 ± 2.4 | 5.9 ± 2.3 |
| <2 years’ disease duration | 5.9 ± 1.9 | 5.6 ± 2.6 | 5.8 ± 2.2 |
| ≥2 years’ disease duration | 6.1 ± 2.3 | 5.9 ± 2.4 | 6.0 ± 2.3 |
| Prior anti‐TNF use, no. (%) | 194 (52.7) | 213 (58.4) | 407 (55.5) |
| Rheumatoid factor | |||
| No. (%) positiveb | 251 (72.3) | 242 (69.9) | 493 (71.1) |
| No. (%) with prior anti‐TNF usec | 142 (56.6) | 149 (61.6) | 291 (59.0) |
| Anti‐CCP antibody | |||
| No. (%) positived | 227 (93.8) | 234 (94.0) | 461 (93.9) |
| No. (%) with prior anti‐TNF usee | 128 (56.4) | 148 (63.2) | 276 (59.9) |
RA = rheumatoid arthritis; DAS28‐ESR = Disease Activity Score in 28 joints using the erythrocyte sedimentation rate; SDAI = Simplified Disease Activity Index; CRP = C‐reactive protein; MDHAQ = Multidimensional Health Assessment Questionnaire; anti‐TNF = anti–tumor necrosis factor.
Above the normal reference range of 0–14 IU/ml for rheumatoid factor. Data were available for 693 patients: 347 in the Routine Assessment of Patient Index Data 3 (RAPID‐3) assessment arm and 346 in the Clinical Disease Activity Index (CDAI) assessment arm.
Of the rheumatoid factor–positive patients.
Above the normal reference range of 0–5 IU/ml for anti–cyclic citrullinated peptide (anti‐CCP). Data were available for 491 patients: 242 in the RAPID‐3 assessment arm and 249 in the CDAI assessment arm.
Of the anti‐CCP antibody–positive patients.